www.idosr.org Winniefred, 2025
©IDOSR PUBLICATIONS ISSN: 2579-0781

International Digital Organization for Scientific Research IDOSRJES11200000
IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 17-23, 2025.
https://doi.org/10.59298/IDOSR/JES/112.1723

Nanotechnology and Gut Microbiome Modulation in Obesity

Winniefred Nankya

Department of Clinical Pharmacy Kampala International University Uganda
Email:winniefred.nankya@studwc.kiu.ac.ug

ABSTRACT

The gut microbiome plays a pivotal role in obesity pathogenesis by influencing nutrient absorption, energy metabolism, inflammation, and host signaling pathways. Dysbiosis imbalances in microbial composition has been linked to weight gain, insulin resistance, and obesity-associated comorbidities. Modulating the microbiome using probiotics, prebiotics, synbiotics, postbiotics, and microbial metabolites offers promising therapeutic strategies. However, conventional delivery approaches are limited by poor viability, degradation in the gastrointestinal tract, and inconsistent colonization. Nanotechnology provides innovative solutions by protecting microbial agents, enhancing bioavailability of metabolites, and enabling targeted delivery to specific intestinal regions. This review explores the principles of nanotechnology in microbiome modulation, recent advances in obesity management, translational challenges, clinical perspectives, and future opportunities. By integrating nanotechnology with microbiome-based interventions, obesity management can advance toward precision and sustainable therapies.

Keywords: Nanotechnology, Gut microbiome, Obesity, Probiotics, Targeted delivery

INTRODUCTION

The human gut microbiome comprising trillions of bacteria, archaea, viruses, and fungi has emerged as a key regulator of metabolic health[1–3]. It participates in digestion, energy harvest, immune modulation, and production of bioactive metabolites such as short-chain fatty acids (SCFAs). Growing evidence links gut microbiota composition to obesity, insulin resistance, and systemic inflammation. Studies show that obese individuals often harbor altered microbial profiles, characterized by reduced diversity and increased Firmicutes-to-Bacteroidetes ratios [4]. These shifts enhance energy harvest from the diet, promote fat storage, and contribute to chronic low-grade inflammation, central to obesity pathophysiology[5].

Modulating the gut microbiome represents a promising therapeutic avenue. Approaches include probiotics (live beneficial microorganisms), prebiotics (non-digestible fibers that stimulate beneficial microbial growth), synbiotics (probiotic–prebiotic combinations), postbiotics (bioactive microbial products), and fecal microbiota transplantation (FMT). While these strategies show promise, several challenges limit their efficacy[6–9]. Probiotic strains often fail to survive gastric acidity and bile salts, reducing colonization. Prebiotics may exhibit inconsistent efficacy depending on individual microbiota composition. Postbiotics and microbial metabolites degrade rapidly in the gastrointestinal tract. Moreover, targeted delivery to specific gut regions remains difficult, leading to suboptimal outcomes[10].

Nanotechnology offers unique advantages to overcome these barriers. Nanocarriers including lipid nanoparticles, polymeric nanoparticles, dendrimers, micelles, and nanoemulsions can encapsulate probiotics, prebiotics, or metabolites, protecting them from degradation and ensuring controlled release in the colon[11–15]. Mucoadhesive nanoparticles enhance retention on intestinal mucosa, improving colonization. Functionalization with ligands allows targeted delivery to inflamed or metabolically active gut regions. Smart, stimuli-responsive nanocarriers can release their payloads in response to pH, enzymatic activity, or microbial metabolites, ensuring precision delivery[16–20].

In obesity management, nanotechnology-enhanced microbiome modulation offers multiple benefits. Encapsulation of SCFAs or bile acid modulators can enhance their stability and absorption, directly influencing lipid metabolism and satiety signaling. Nanoparticles delivering probiotics improve strain survival and colonization, increasing efficacy in restoring microbial balance. Similarly, nano-prebiotics enhance fermentation efficiency, producing more SCFAs and beneficial metabolites[21, 22].

The integration of nanotechnology and microbiome modulation aligns with the growing emphasis on personalized medicine. Given the variability of gut microbiota between individuals, personalized nanoformulations may be tailored to specific microbial profiles, maximizing therapeutic benefit[23–25]. Moreover, combining microbiome-targeted nanotechnology with digital health tools for real-time monitoring could allow adaptive interventions based on individual responses [26]. This review examines the role of nanotechnology in gut microbiome modulation for obesity management. Section 2 outlines the principles of nanotechnology in microbiome-targeted delivery. Section 3 highlights advances in obesity research, focusing on probiotic, prebiotic, and metabolite nanoformulations. Section 4 discusses translational barriers. Section 5 explores clinical perspectives. Section 6 outlines future directions, including personalized nano-microbiome therapeutics and integration with multi-omics approaches.

2. Principles of Nanotechnology in Gut Microbiome Modulation (≈650 words)

The application of nanotechnology in gut microbiome modulation rests on its ability to overcome the intrinsic barriers associated with conventional delivery of probiotics, prebiotics, and microbial metabolites. The gastrointestinal (GI) tract presents a hostile environment for these agents, characterized by acidic pH in the stomach, bile salts in the small intestine, digestive enzymes, and variable transit times[27]. Probiotics, in particular, are highly sensitive to these conditions, with many strains failing to survive in sufficient numbers to colonize the colon. Similarly, bioactive microbial metabolites such as short-chain fatty acids (SCFAs) or secondary bile acids degrade rapidly or are absorbed prematurely, limiting their therapeutic effect. Nanotechnology addresses these limitations by protecting therapeutic agents, enhancing their stability and absorption, and enabling targeted delivery[28].

Encapsulation and protection of probiotics and bioactives: Encapsulation is one of the most fundamental principles. Probiotics can be enclosed in lipid nanoparticles, polymeric matrices, or alginate-based nanogels that shield them from gastric acid and bile salts, significantly improving survival during transit[29, 30]. Likewise, nanoencapsulation of SCFAs or polyphenol-derived prebiotics stabilizes these molecules, preserving bioactivity until they reach the colon. Encapsulation also prevents premature interactions with other dietary components or enzymes, ensuring greater consistency in therapeutic outcomes[30].

Controlled and site-specific release: Another central principle is the ability to achieve controlled and site-specific release. Smart, stimuli-responsive nanocarriers are designed to exploit environmental triggers unique to the GI tract. For example, pH-sensitive carriers remain stable in the highly acidic stomach but disintegrate in the neutral-to-alkaline pH of the intestine, releasing probiotics or metabolites precisely where they are most needed. Enzyme-responsive nanocarriers degrade in the presence of colonic bacterial enzymes, ensuring release of prebiotics or synbiotics only in the colon, thereby maximizing their effectiveness[31, 32].

Mucoadhesion and colonization enhancement: The intestinal mucosa is the first barrier probiotics must adhere to in order to colonize effectively. Conventional probiotics are often cleared rapidly with intestinal transit, limiting their persistence[33]. Nanocarriers functionalized with mucoadhesive polymers such as chitosan prolong retention time by binding to mucin, increasing the chances of colonization and sustained therapeutic benefit. These systems also improve the interaction between delivered probiotics and host epithelial cells, enhancing immunomodulatory effects[34, 35].

Surface functionalization and targeting: Surface modification expands the scope of nanocarrier applications by enabling selective targeting of microbial populations or intestinal regions. For instance, nanoparticles decorated with mannose or fucose ligands can interact with gut epithelial receptors that naturally recognize these sugars, improving uptake and retention. Similarly, targeting ligands such as antibodies or peptides can direct nanocarriers toward inflamed or metabolically active gut regions, where microbiome modulation is most critical in obesity[36].

Co-delivery and synergistic approaches: Nanotechnology also enables co-encapsulation of different therapeutic agents, allowing synergistic effects. Synbiotic nanocarriers that combine probiotics and prebiotics within the same delivery system enhance both survival and activity of probiotic strains. For example, a Lactobacillus strain encapsulated with inulin within a polymeric nanoparticle not only survives gastric transit but also finds its preferred substrate upon release, enhancing colonization and SCFA production. Similarly, SCFAs can be co-delivered with anti-inflammatory compounds, producing dual effects of metabolic regulation and inflammation reduction[37, 38].

Improved absorption of microbial metabolites: Microbial metabolites such as butyrate, propionate, and secondary bile acids play a central role in regulating host metabolism and appetite. However, their therapeutic use is limited by instability and rapid clearance. Nanocarrier systems, particularly lipid-based and polymeric nanoparticles, improve their intestinal absorption and systemic bioavailability. Encapsulation also allows sustained release, ensuring steady levels of these metabolites for longer durations[39, 40].

Theranostic potential in microbiome modulation: An emerging principle is the integration of therapeutic delivery with diagnostic capabilities, known as theranostics. Nanoparticles can be engineered to carry imaging agents alongside probiotics or metabolites, allowing real-time monitoring of colonization and therapeutic outcomes. For instance, magnetic nanoparticles delivering probiotics can simultaneously enable MRI-based

visualization of intestinal colonization patterns. This dual functionality is particularly relevant in obesity research, where tracking microbiome changes is crucial for understanding treatment efficacy[41–43].
Biocompatibility and safety considerations: Finally, the design of nanocarriers must prioritize safety and compatibility with the gut ecosystem. Materials such as lipids, chitosan, alginate, and PLGA are commonly used due to their biodegradability and minimal toxicity. Importantly, nanocarriers must avoid unintended disruption of microbial balance or immune activation. The principle of "do no harm" is central, ensuring that modulation is beneficial rather than detrimental. In sum, the principles of nanotechnology in gut microbiome modulation encompass protection, controlled release, mucoadhesion, surface functionalization, co-delivery, improved metabolite absorption, theranostic integration, and biocompatibility. Collectively, these features enable precise, efficient, and safe modulation of the microbiome, offering transformative potential for obesity management[44–47].

3. Advances in Obesity Management via Nano-Microbiome Modulation

Preclinical and emerging clinical studies highlight the promise of nano-enabled microbiome modulation in obesity.
Probiotic nanoformulations improve survival of Lactobacillus and Bifidobacterium strains during gastrointestinal transit. Encapsulation in lipid nanoparticles or chitosan-based systems enhances colonization, leading to improved lipid metabolism and reduced fat accumulation in obese models[48].
Nano-prebiotics have been developed using nanoemulsions and polymeric carriers to deliver fibers or oligosaccharides directly to the colon. These formulations increase SCFA production, improve satiety signaling, and reduce inflammation[49].
Postbiotic nanoformulations encapsulating SCFAs or microbial metabolites improve stability and absorption. Butyrate-loaded nanoparticles, for example, enhance gut barrier integrity, reduce systemic inflammation, and improve insulin sensitivity in obese rodents[50].
Synbiotic nanocarriers combining probiotics and prebiotics have shown synergistic effects, increasing microbial diversity and reducing weight gain[51].
Fecal microbiota-derived metabolites delivered via nanoparticles represent a novel approach, with studies showing improvements in glucose tolerance and lipid metabolism. These advances underscore how nanotechnology enhances microbiome-based therapies, amplifying their impact on obesity management[52].

4. Translational Challenges

Several barriers hinder the translation of nano-microbiome therapies into clinical practice.
Safety concerns: Long-term effects of nanoparticles on gut epithelium and microbiota remain poorly understood. Some materials may disrupt microbial balance or accumulate in tissues.[53]
Manufacturing challenges: Scaling production of consistent, reproducible probiotic nanoformulations is technically demanding. Ensuring viability of live microorganisms during encapsulation and storage is particularly complex[54].
Regulatory hurdles: Probiotic nanoformulations fall into a regulatory gray area between food supplements and pharmaceuticals, complicating approval. Demonstrating safety, efficacy, and reproducibility is essential.[55]
Patient variability: Microbiota composition varies significantly between individuals, leading to heterogeneous responses. Personalized approaches may be required, but these add complexity and cost[56].
Cost-effectiveness: Advanced nanoformulations may be expensive to develop and produce. Without demonstrating clear advantages over conventional probiotics, widespread adoption may be limited[57, 58].
Addressing these challenges requires multidisciplinary collaboration, standardized protocols, and robust long-term clinical studies.

5. Clinical Perspectives

Clinically, nano-enabled microbiome modulation has the potential to revolutionize obesity treatment. By improving the stability and bioavailability of probiotics and metabolites, nanoformulations can enhance efficacy compared to conventional supplements[59]. Oral delivery remains the most practical route. Lipid- and polymer-based encapsulated probiotics have already demonstrated improved viability in small human trials, showing enhanced metabolic outcomes. Nano-prebiotic beverages are being explored as functional foods, offering patient-friendly approaches[60].
Integration with existing obesity treatments is also promising. Nanoformulated probiotics could complement GLP-1 receptor agonists or bariatric surgery, enhancing metabolic improvements. Similarly, butyrate nanoparticles could be used alongside dietary interventions to strengthen gut barrier function and reduce inflammation[60].
Adoption will depend on demonstrating long-term safety, patient acceptability, and cost-effectiveness. Public trust and regulatory clarity are essential, especially as microbiome therapies often fall between food and drug categories.

6. Future Directions

Future innovations will focus on **personalized nano-microbiome therapies**. By integrating microbiome sequencing with nanoformulation design, interventions can be tailored to individual microbial profiles for maximum efficacy.

Multi-functional platforms combining probiotics, prebiotics, and metabolites in a single nanocarrier could provide synergistic effects, restoring microbial balance and metabolic health simultaneously.

Smart stimuli-responsive systems will enhance precision, releasing probiotics or metabolites in response to gut-specific triggers such as pH, enzymes, or microbial metabolites.

Integration with **multi-omics approaches** (metabolomics, proteomics, metagenomics) will enable comprehensive monitoring of therapeutic outcomes.

Finally, **digital health integration** linking nanosensor-based gut monitoring with nanoformulated interventions could create adaptive, closed-loop systems for obesity management.

If these advances succeed, nano-microbiome modulation could become a cornerstone of precision medicine for obesity.

CONCLUSION

Nanotechnology offers transformative opportunities to enhance microbiome-targeted therapies for obesity. By improving stability, bioavailability, and precision, nanoformulations of probiotics, prebiotics, postbiotics, and microbial metabolites overcome longstanding barriers of conventional delivery. While challenges in safety, regulation, and personalization remain, future innovations promise to establish nano-microbiome strategies as central tools in combating obesity and its complications.

REFERENCES

1. Banc, R., Rusu, M.E., Filip, L., Popa, D.-S.: The Impact of Ellagitannins and Their Metabolites through Gut Microbiome on the Gut Health and Brain Wellness within the Gut–Brain Axis. Foods. 12, 270 (2023). https://doi.org/10.3390/foods12020270
2. Diener, C., Reyes-Escogido, M. de L., Jimenez-Ceja, L.M., Matus, M., Gomez-Navarro, C.M., Chu, N.D., Zhong, V., Tejero, M.E., Alm, E., Resendis-Antonio, O., Guardado-Mendoza, R.: Progressive Shifts in the Gut Microbiome Reflect Prediabetes and Diabetes Development in a Treatment-Naive Mexican Cohort. Front. Endocrinol. 11, 602326 (2021). https://doi.org/10.3389/fendo.2020.602326
3. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Obeagu, E.I.: Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 103, e38088 (2024). https://doi.org/10.1097/MD.0000000000038088
4. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
5. Gomes, A.C., Hoffmann, C., Mota, J.F.: The human gut microbiota: Metabolism and perspective in obesity. Gut Microbes. 9, 308–325 (2018). https://doi.org/10.1080/19490976.2018.1465157
6. Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov. Oncol. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2
7. Li, R., Andreu-Sánchez, S., Kuipers, F., Fu, J.: Gut microbiome and bile acids in obesity-related diseases. Best Pract. Res. Clin. Endocrinol. Metab. 35, 101493 (2021). https://doi.org/10.1016/j.beem.2021.101493
8. Zhang, P.: Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. Int. J. Mol. Sci. 23, 9588 (2022). https://doi.org/10.3390/ijms23179588
9. Zsálig, D., Berta, A., Tóth, V., Szabó, Z., Simon, K., Figler, M., Pusztafalvi, H., Polyák, É.: A Review of the Relationship between Gut Microbiome and Obesity. Appl. Sci. 13, 610 (2023). https://doi.org/10.3390/app13010610
10. Abdul Manan, M.: The role of probiotics in personalized therapeutics: Advances in gut microbe-driven interventions. The Microbe. 8, 100497 (2025). https://doi.org/10.1016/j.microb.2025.100497
11. Al Tahan, M.A., Al-Khattawi, A., Russell, C.: Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers. J. Drug Deliv. Sci. Technol. 112, 107205 (2025). https://doi.org/10.1016/j.jddst.2025.107205
12. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
13. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
14. Magadani, R., Ndinteh, D.T., Roux, S., Nangah, L.P., Atangwho, I.J., Uti, D.E., Alum, E.U., Egba, S.I.: Cytotoxic Effects of Lecaniodiscus Cupanioides (Planch.) Extract and Triterpenoids-derived Gold

Nanoparticles On MCF-7 Breast Cancer Cell Lines. Anti-Cancer Agents Med. Chem. Former. Curr. Med. Chem. - Anti-Cancer Agents. 25, 841–850 (2025). https://doi.org/10.2174/0118715206325529241004064307
15. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
16. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
17. Du, J., Lane, L.A., Nie, S.: Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment. J. Control. Release Off. J. Control. Release Soc. 219, 205–214 (2015). https://doi.org/10.1016/j.jconrel.2015.08.050
18. Khalil, A.K.A., Teow, Y.H., Takriff, M.S., Ahmad, A.L., Atieh, M.A.: Recent developments in stimuli-responsive polymer for emerging applications: A review. Results Eng. 25, 103900 (2025). https://doi.org/10.1016/j.rineng.2024.103900
19. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542
20. Majumder, J., Minko, T.: Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin. Drug Deliv. 18, 205–227 (2021). https://doi.org/10.1080/17425247.2021.1828339
21. Dahiya, D.K., Renuka, Puniya, M., Shandilya, U.K., Dhewa, T., Kumar, N., Kumar, S., Puniya, A.K., Shukla, P.: Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review. Front. Microbiol. 8, 563 (2017). https://doi.org/10.3389/fmicb.2017.00563
22. Baek, K.-R., Singh, S., Hwang, H.-S., Seo, S.-O.: Using Gut Microbiota Modulation as a Precision Strategy Against Obesity. Int. J. Mol. Sci. 26, 6282 (2025). https://doi.org/10.3390/ijms26136282
23. Li, X., Wei, H., Qi, J., Ma, K., Luo, Y., Weng, L.: Interactions of Nanomaterials with Gut Microbiota and Their Applications in Cancer Therapy. Sensors. 23, 4428 (2023). https://doi.org/10.3390/s23094428
24. Khurana, A., Hartmann, P.: Gut microbiome-specific nanoparticle-based therapeutics for liver diseases. World J. Gastroenterol. 31, 109105 (2025). https://doi.org/10.3748/wjg.v31.i27.109105
25. Törős, G., Gulyás, G., El-Ramady, H., Alibrahem, W., Muthu, A., Gangakhedkar, P., Atieh, R., Prokisch, J.: Sustainable Nanotechnology Strategies for Modulating the Human Gut Microbiota. Int. J. Mol. Sci. 26, 5433 (2025). https://doi.org/10.3390/ijms26125433
26. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
27. Stamatopoulos, K., O'Farrell, C., Simmons, M., Batchelor, H.: In vivo models to evaluate ingestible devices: Present status and current trends. Adv. Drug Deliv. Rev. 177, 113915 (2021). https://doi.org/10.1016/j.addr.2021.113915
28. Markowiak-Kopeć, P., Śliżewska, K.: The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. Nutrients. 12, 1107 (2020). https://doi.org/10.3390/nu12041107
29. Agriopoulou, S., Tarapoulouzi, M., Varzakas, T., Jafari, S.M.: Application of Encapsulation Strategies for Probiotics: From Individual Loading to Co-Encapsulation. Microorganisms. 11, 2896 (2023). https://doi.org/10.3390/microorganisms11122896
30. Arratia-Quijada, J., Nuño, K., Ruíz-Santoyo, V., Andrade-Espinoza, B.A.: Nano-encapsulation of probiotics: Need and critical considerations to design new non-dairy probiotic products. J. Funct. Foods. 116, 106192 (2024). https://doi.org/10.1016/j.jff.2024.106192
31. Karimi, M., Eslami, M., Sahandi-Zangabad, P., Mirab, F., Farajisafiloo, N., Shafaei, Z., Ghosh, D., Bozorgomid, M., Dashkhaneh, F., Hamblin, M.R.: pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8, 696–716 (2016). https://doi.org/10.1002/wnan.1389
32. Xie, Z., Guo, W., Guo, N., Huangfu, M., Liu, H., Lin, M., Xu, W., Chen, J., Wang, T., Wei, Q., Han, M., Gao, J.: Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy. Acta Biomater. 71, 351–362 (2018). https://doi.org/10.1016/j.actbio.2018.03.013

33. Han, S., Lu, Y., Xie, J., Fei, Y., Zheng, G., Wang, Z., Liu, J., Lv, L., Ling, Z., Berglund, B., Yao, M., Li, L.: Probiotic Gastrointestinal Transit and Colonization After Oral Administration: A Long Journey. Front. Cell. Infect. Microbiol. 11, 609722 (2021). https://doi.org/10.3389/fcimb.2021.609722
34. Kumar, R., Islam, T., Nurunnabi, M.: Mucoadhesive carriers for oral drug delivery. J. Control. Release Off. J. Control. Release Soc. 351, 504–559 (2022). https://doi.org/10.1016/j.jconrel.2022.09.024
35. Gonciarz, W., Balcerczak, E., Brzeziński, M., Jeleń, A., Pietrzyk-Brzezińska, A.J., Narayanan, V.H.B., Chmiela, M.: Chitosan-based formulations for therapeutic applications. A recent overview. J. Biomed. Sci. 32, 62 (2025). https://doi.org/10.1186/s12929-025-01161-7
36. Priya, S., Desai, V.M., Singhvi, G.: Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery. ACS Omega. 8, 74–86 (2022). https://doi.org/10.1021/acsomega.2c05976
37. Smolinska, S., Popescu, F.-D., Zemelka-Wiacek, M.: A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity. J. Clin. Med. 14, 3673 (2025). https://doi.org/10.3390/jcm14113673
38. Naeem, H., Shahbaz, M., Farooq, U., Ahmad, T.: Development and Characterization of Synbiotic Microbeads for Enhanced Viability of Probiotics for Food Applications. J. Food Sci. 90, e70390 (2025). https://doi.org/10.1111/1750-3841.70390
39. Xu, X., Wang, M., Wang, Z., Chen, Q., Chen, X., Xu, Y., Dai, M., Wu, B., Li, Y.: The bridge of the gut–joint axis: Gut microbial metabolites in rheumatoid arthritis. Front. Immunol. 13, 1007610 (2022). https://doi.org/10.3389/fimmu.2022.1007610
40. Yoon, J.-H., Do, J.-S., Velankanni, P., Lee, C.-G., Kwon, H.-K.: Gut Microbial Metabolites on Host Immune Responses in Health and Disease. Immune Netw. 23, e6 (2023). https://doi.org/10.4110/in.2023.23.e6
41. AlQurashi, D.M., AlQurashi, T.F., Alam, R.I., Shaikh, S., Tarkistani, M.A.M.: Advanced Nanoparticles in Combating Antibiotic Resistance: Current Innovations and Future Directions. J. Nanotheranostics. 6, 9 (2025). https://doi.org/10.3390/jnt6020009
42. Bu, T., Li, Z., Hou, Y., Sun, W., Zhang, R., Zhao, L., Wei, M., Yang, G., Yuan, L.: Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment. Theranostics. 11, 9988–10000 (2021). https://doi.org/10.7150/thno.64229
43. Chandrasekharan, P., Tay, Z.W., Hensley, D., Zhou, X.Y., Fung, B.K., Colson, C., Lu, Y., Fellows, B.D., Huynh, Q., Saayujya, C., Yu, E., Orendorff, R., Zheng, B., Goodwill, P., Rinaldi, C., Conolly, S.: Using magnetic particle imaging systems to localize and guide magnetic hyperthermia treatment: tracers, hardware, and future medical applications. Theranostics. 10, 2965–2981 (2020). https://doi.org/10.7150/thno.40858
44. El-Hammadi, M.M., Arias, J.L.: Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines. Nanomaterials. 12, 354 (2022). https://doi.org/10.3390/nano12030354
45. Horvath, D., Basler, M.: PLGA Particles in Immunotherapy. Pharmaceutics. 15, 615 (2023). https://doi.org/10.3390/pharmaceutics15020615
46. Omidian, H., Wilson, R.L.: PLGA Implants for Controlled Drug Delivery and Regenerative Medicine: Advances, Challenges, and Clinical Potential. Pharmaceuticals. 18, 631 (2025). https://doi.org/10.3390/ph18050631
47. Yang, J., Zeng, H., Luo, Y., Chen, Y., Wang, M., Wu, C., Hu, P.: Recent Applications of PLGA in Drug Delivery Systems. Polymers. 16, 2606 (2024). https://doi.org/10.3390/polym16182606
48. Lopes, S.A., Roque-Borda, C.A., Duarte, J.L., Di Filippo, L.D., Borges Cardoso, V.M., Pavan, F.R., Chorilli, M., Meneguin, A.B.: Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease—An Overview. Pharmaceutics. 15, 2600 (2023). https://doi.org/10.3390/pharmaceutics15112600
49. Yoo, S., Jung, S.-C., Kwak, K., Kim, J.-S.: The Role of Prebiotics in Modulating Gut Microbiota: Implications for Human Health. Int. J. Mol. Sci. 25, 4834 (2024). https://doi.org/10.3390/ijms25094834
50. Yilmaz, Y.: Postbiotics as Antiinflammatory and Immune-Modulating Bioactive Compounds in Metabolic Dysfunction-Associated Steatotic Liver Disease. Mol. Nutr. Food Res. 68, 2400754 (2024). https://doi.org/10.1002/mnfr.202400754
51. Hong, L., Lee, S.-M., Kim, W.-S., Choi, Y.-J., Oh, S.-H., Li, Y.-L., Choi, S.-H., Chung, D.H., Jung, E., Kang, S.-K., Cho, C.-S.: Synbiotics Containing Nanoprebiotics: A Novel Therapeutic Strategy to Restore Gut Dysbiosis. Front. Microbiol. 12, (2021). https://doi.org/10.3389/fmicb.2021.715241
52. Gong, Y., Liu, Z., Zhou, P., Li, J., Miao, Y.-B.: Biomimetic nanocarriers harnessing microbial metabolites usher the path for brain disease therapy. Nano TransMed. 2, 100020 (2023). https://doi.org/10.1016/j.ntm.2023.100020
53. van Wyk, A.S., Prinsloo, G.: Health, safety and quality concerns of plant-based traditional medicines and herbal remedies. South Afr. J. Bot. 133, 54–62 (2020). https://doi.org/10.1016/j.sajb.2020.06.031

54. Kara, A., Ongoren, B., Anaya, B.J., Lalatsa, A., Serrano, D.R.: Continuous manufacturing of nanomedicines using 3D-printed microfluidic devices. Appl. Mater. Today. 43, 102672 (2025). https://doi.org/10.1016/j.apmt.2025.102672
55. 4dm1n_diversatechnologies: Overcoming regulatory hurdles in clinical translation of nanomedicine, https://www.diversatechnologies.com/overcoming-regulatory-hurdles-in-clinical-translation-of-nanomedicine/, (2025)
56. Goldiş, A., Dragomir, R., Mercioni, M.A., Goldiş, C., Sirca, D., Enătescu, I., Olariu, L., Belei, O.: Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach. Microorganisms. 13, 1047 (2025). https://doi.org/10.3390/microorganisms13051047
57. Petrovic, S., Bita, B., Barbinta-Patrascu, M.-E.: Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives. Int. J. Mol. Sci. 25, 5842 (2024). https://doi.org/10.3390/ijms25115842
58. Gomes, M., Ramalho, M.J., Loureiro, J.A., Pereira, M.C.: Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry. Pharmaceutics. 17, 661 (2025). https://doi.org/10.3390/pharmaceutics17050661
59. Kadam, O., Dalai, S., Chauhan, B., Guru, R.R., Mitra, S., Raytekar, N., Kumar, R.: Nanobiotechnology Unveils the Power of Probiotics: A Comprehensive Review on the Synergistic Role of Probiotics and Advanced Nanotechnology in Enhancing Geriatric Health. Cureus. 17, e80478. https://doi.org/10.7759/cureus.80478
60. Martelli, A., Mohamed, Y.O.A., Gallego-Ferrer, G., Gentile, P., Girón-Hernández, J.: Revolutionizing gut health: advances in encapsulation strategies for probiotics and bioactive molecules. Biotechnol. Adv. 83, 108630 (2025). https://doi.org/10.1016/j.biotechadv.2025.108630

CITE AS: Winniefred Nankya (2025). Nanotechnology and Gut Microbiome Modulation in Obesity. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 17-23. https://doi.org/10.59298/IDOSR/JES/112.1723